{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T07:37:29Z","timestamp":1785915449838,"version":"3.56.0"},"reference-count":100,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,6,3]],"date-time":"2023-06-03T00:00:00Z","timestamp":1685750400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,6,3]],"date-time":"2023-06-03T00:00:00Z","timestamp":1685750400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Aging Mind Foundation Dallas Barbara Wallace and Kelly King Charitable Foundation Trust Baylor Scott & White Foundation"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Parkinsons Dis."],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>We performed liquid chromatography tandem mass spectrometry analysis with the targeted metabolomic kit Biocrates MxP Quant 500, in human brain cortex (Brodmann area 9) and putamen, to reveal metabolic changes characteristic of Parkinson\u2019s disease (PD) and PD-related cognitive decline. This case-control study involved 101 subjects (33 PD without dementia, 32 PD with dementia (cortex only), 36 controls). We found changes associated with PD, cognitive status, levodopa levels, and disease progression. The affected pathways include neurotransmitters, bile acids, homocysteine metabolism, amino acids, TCA cycle, polyamines, \u03b2-alanine metabolism, fatty acids, acylcarnitines, ceramides, phosphatidylcholines, and several microbiome-derived metabolites. Previously reported levodopa-related homocysteine accumulation in cortex still best explains the dementia status in PD, which can be modified by dietary supplementation. Further investigation is needed to reveal the exact mechanisms behind this pathological change.<\/jats:p>","DOI":"10.1038\/s41531-023-00531-y","type":"journal-article","created":{"date-parts":[[2023,6,3]],"date-time":"2023-06-03T14:01:44Z","timestamp":1685800904000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["Targeted metabolomic analysis in Parkinson\u2019s disease brain frontal cortex and putamen with relation to cognitive impairment"],"prefix":"10.1038","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4212-6811","authenticated-orcid":false,"given":"Karel","family":"Kaleck\u00fd","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4199-7551","authenticated-orcid":false,"given":"Teodoro","family":"Bottiglieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,6,3]]},"reference":[{"key":"531_CR1","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/S1474-4422(18)30295-3","volume":"17","author":"GBD 2016 Parkinson\u2019s Disease Collaborators.","year":"2018","unstructured":"GBD 2016 Parkinson\u2019s Disease Collaborators. Global, regional, and national burden of Parkinson\u2019s disease, 1990\u20132016: A systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 17, 939\u2013953 (2018).","journal-title":"Lancet Neurol."},{"key":"531_CR2","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1212\/WNL.56.6.730","volume":"56","author":"D Aarsland","year":"2001","unstructured":"Aarsland, D. et al. Risk of dementia in Parkinson\u2019s disease: A community-based, prospective study. Neurology 56, 730\u2013736 (2001).","journal-title":"Neurology"},{"key":"531_CR3","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1038\/nrn3549","volume":"14","author":"DJ Irwin","year":"2013","unstructured":"Irwin, D. J., Lee, V. M.-Y. & Trojanowski, J. Q. Parkinson\u2019s disease dementia: Convergence of \u03b1-synuclein, tau and amyloid-\u03b2 pathologies. Nat. Rev. Neurosci. 14, 626\u2013636 (2013).","journal-title":"Nat. Rev. Neurosci."},{"key":"531_CR4","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1016\/S0140-6736(14)61393-3","volume":"386","author":"LV Kalia","year":"2015","unstructured":"Kalia, L. V. & Lang, A. E. Parkinson\u2019s disease. Lancet 386, 896\u2013912 (2015).","journal-title":"Lancet"},{"key":"531_CR5","doi-asserted-by":"publisher","first-page":"120015","DOI":"10.1016\/j.jns.2021.120015","volume":"433","author":"C Koros","year":"2022","unstructured":"Koros, C., Stefanis, L. & Scarmeas, N. Parkinsonism and dementia. J. Neurol. Sci. 433, 120015 (2022).","journal-title":"J. Neurol. Sci."},{"key":"531_CR6","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/0304-3940(86)90320-4","volume":"67","author":"TL Perry","year":"1986","unstructured":"Perry, T. L. & Yong, V. W. Idiopathic Parkinson\u2019s disease, progressive supranuclear palsy and glutathione metabolism in the substantia nigra of patients. Neurosci. Lett. 67, 269\u2013274 (1986).","journal-title":"Neurosci. Lett."},{"key":"531_CR7","doi-asserted-by":"publisher","first-page":"569","DOI":"10.3390\/metabo11090569","volume":"11","author":"M Scholefield","year":"2021","unstructured":"Scholefield, M. et al. Substantively lowered levels of pantothenic acid (vitamin B5) in several regions of the human brain in Parkinson\u2019s disease dementia. Metabolites 11, 569 (2021).","journal-title":"Metabolites"},{"key":"531_CR8","doi-asserted-by":"publisher","first-page":"711396","DOI":"10.3389\/fnmol.2021.711396","volume":"14","author":"M Scholefield","year":"2021","unstructured":"Scholefield, M. et al. Severe and regionally widespread increases in tissue urea in the human brain represent a novel finding of pathogenic potential in Parkinson\u2019s disease dementia. Front. Mol. Neurosci. 14, 711396 (2021).","journal-title":"Front. Mol. Neurosci."},{"key":"531_CR9","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/S0304-3940(01)01776-1","volume":"304","author":"M Viv\u00f3","year":"2001","unstructured":"Viv\u00f3, M. et al. Polyamines in the basal ganglia of human brain. Influence of aging and degenerative movement disorders. Neurosci. Lett. 304, 107\u2013111 (2001).","journal-title":"Neurosci. Lett."},{"key":"531_CR10","doi-asserted-by":"publisher","first-page":"e17299","DOI":"10.1371\/journal.pone.0017299","volume":"6","author":"D Cheng","year":"2011","unstructured":"Cheng, D. et al. Lipid pathway alterations in Parkinson\u2019s disease primary visual cortex. PLoS One 6, e17299 (2011).","journal-title":"PLoS One"},{"key":"531_CR11","doi-asserted-by":"publisher","first-page":"e0191815","DOI":"10.1371\/journal.pone.0191815","volume":"13","author":"PL Wood","year":"2018","unstructured":"Wood, P. L., Tippireddy, S., Feriante, J. & Woltjer, R. L. Augmented frontal cortex diacylglycerol levels in Parkinson\u2019s disease and Lewy Body Disease. PLoS One 13, e0191815 (2018).","journal-title":"PLoS One"},{"key":"531_CR12","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.3390\/cells9091966","volume":"9","author":"H Xicoy","year":"2020","unstructured":"Xicoy, H., Brouwers, J. F., Wieringa, B. & Martens, G. J. M. Explorative combined lipid and transcriptomic profiling of substantia nigra and putamen in Parkinson\u2019s disease. Cells 9, 1966 (2020).","journal-title":"Cells"},{"key":"531_CR13","doi-asserted-by":"publisher","first-page":"187","DOI":"10.3390\/metabo12020187","volume":"12","author":"AW Beger","year":"2022","unstructured":"Beger, A. W., Dudzik, B., Woltjer, R. L. & Wood, P. L. Human brain lipidomics: Pilot analysis of the basal ganglia sphingolipidome in Parkinson\u2019s disease and Lewy body disease. Metabolites 12, 187 (2022).","journal-title":"Metabolites"},{"key":"531_CR14","doi-asserted-by":"publisher","first-page":"599","DOI":"10.3390\/nu14030599","volume":"14","author":"K Kaleck\u00fd","year":"2022","unstructured":"Kaleck\u00fd, K., Ashcraft, P. & Bottiglieri, T. One-carbon metabolism in Alzheimer\u2019s disease and Parkinson\u2019s disease brain tissue. Nutrients 14, 599 (2022).","journal-title":"Nutrients"},{"key":"531_CR15","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1056\/NEJMoa011613","volume":"346","author":"S Seshadri","year":"2002","unstructured":"Seshadri, S. et al. Plasma homocysteine as a risk factor for dementia and Alzheimer\u2019s disease. N. Engl. J. Med. 346, 476\u2013483 (2002).","journal-title":"N. Engl. J. Med."},{"key":"531_CR16","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1001\/archneur.61.5.657","volume":"61","author":"T M\u00fcller","year":"2004","unstructured":"M\u00fcller, T., Renger, K. & Kuhn, W. Levodopa-associated increase of homocysteine levels and sural axonal neurodegeneration. Arch. Neurol. 61, 657\u2013660 (2004).","journal-title":"Arch. Neurol."},{"key":"531_CR17","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1002\/mds.20253","volume":"19","author":"PE O\u2019Suilleabhain","year":"2004","unstructured":"O\u2019Suilleabhain, P. E., Bottiglieri, T., Dewey, R. B. Jr, Sharma, S. & Diaz-Arrastia, R. Modest increase in plasma homocysteine follows levodopa initiation in Parkinson\u2019s disease. Mov. Disord. 19, 1403\u20131408 (2004).","journal-title":"Mov. Disord."},{"key":"531_CR18","doi-asserted-by":"publisher","first-page":"e50496","DOI":"10.1371\/journal.pone.0050496","volume":"7","author":"JY Shin","year":"2012","unstructured":"Shin, J. Y. et al. Elevated homocysteine by levodopa is detrimental to neurogenesis in parkinsonian model. PLoS One 7, e50496 (2012).","journal-title":"PLoS One"},{"key":"531_CR19","doi-asserted-by":"publisher","first-page":"9173","DOI":"10.1523\/JNEUROSCI.0125-12.2012","volume":"32","author":"T Bottiglieri","year":"2012","unstructured":"Bottiglieri, T. et al. Acute administration of L-DOPA induces changes in methylation metabolites, reduced protein phosphatase 2\u2009A methylation, and hyperphosphorylation of Tau protein in mouse brain. J. Neurosci. 32, 9173\u20139181 (2012).","journal-title":"J. Neurosci."},{"key":"531_CR20","doi-asserted-by":"publisher","first-page":"D353","DOI":"10.1093\/nar\/gkw1092","volume":"45","author":"M Kanehisa","year":"2017","unstructured":"Kanehisa, M., Furumichi, M., Tanabe, M., Sato, Y. & Morishima, K. KEGG: New perspectives on genomes, pathways, diseases and drugs. Nucleic Acids Res 45, D353\u2013D361 (2017).","journal-title":"Nucleic Acids Res"},{"key":"531_CR21","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1002\/mds.10473","volume":"18","author":"Movement Disorder Society Task Force on Rating Scales for Parkinson\u2019s Disease.","year":"2003","unstructured":"Movement Disorder Society Task Force on Rating Scales for Parkinson\u2019s Disease. The Unified Parkinson\u2019s Disease Rating Scale (UPDRS): Status and recommendations. Mov. Disord. 18, 738\u2013750 (2003).","journal-title":"Mov. Disord."},{"key":"531_CR22","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1093\/jnen\/nlz080","volume":"78","author":"CH Adler","year":"2019","unstructured":"Adler, C. H. et al. Unified Staging System for Lewy Body disorders: Clinicopathologic correlations and comparison to Braak staging. J. Neuropathol. Exp. Neurol. 78, 891\u2013899 (2019).","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"531_CR23","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/0022-3956(75)90026-6","volume":"12","author":"MF Folstein","year":"1975","unstructured":"Folstein, M. F., Folstein, S. E. & McHugh, P. R. \u201cMini-mental state\u201d. A practical method for grading the cognitive state of patients for the clinician. J. Psychiatr. Res. 12, 189\u2013198 (1975).","journal-title":"J. Psychiatr. Res."},{"key":"531_CR24","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/bs.pbr.2022.01.013","volume":"269","author":"I Frouni","year":"2022","unstructured":"Frouni, I., Kwan, C., Belliveau, S. & Huot, P. Cognition and serotonin in Parkinson\u2019s disease. Prog. Brain Res. 269, 373\u2013403 (2022).","journal-title":"Prog. Brain Res."},{"key":"531_CR25","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s13024-016-0112-5","volume":"11","author":"JR Fisher","year":"2016","unstructured":"Fisher, J. R., Wallace, C. E., Tripoli, D. L., Sheline, Y. I. & Cirrito, J. R. Redundant Gs-coupled serotonin receptors regulate amyloid-\u03b2 metabolism in vivo. Mol. Neurodegener. 11, 45 (2016).","journal-title":"Mol. Neurodegener."},{"key":"531_CR26","doi-asserted-by":"publisher","first-page":"75","DOI":"10.3390\/toxics3010075","volume":"3","author":"BJ Stansley","year":"2015","unstructured":"Stansley, B. J. & Yamamoto, B. K. L-dopa and brain serotonin system dysfunction. Toxics 3, 75\u201388 (2015).","journal-title":"Toxics"},{"key":"531_CR27","doi-asserted-by":"publisher","first-page":"593026","DOI":"10.3389\/fphys.2020.593026","volume":"11","author":"S Al-Bachari","year":"2020","unstructured":"Al-Bachari, S., Naish, J. H., Parker, G. J. M., Emsley, H. C. A. & Parkes, L. M. Blood-brain barrier leakage is increased in Parkinson\u2019s disease. Front. Physiol. 11, 593026 (2020).","journal-title":"Front. Physiol."},{"key":"531_CR28","doi-asserted-by":"publisher","first-page":"e0080521","DOI":"10.1128\/mSystems.00805-21","volume":"6","author":"LN Lucas","year":"2021","unstructured":"Lucas, L. N. et al. Dominant bacterial phyla from the human gut show widespread ability to transform and conjugate bile acids. mSystems 6, e0080521 (2021).","journal-title":"mSystems"},{"key":"531_CR29","doi-asserted-by":"publisher","DOI":"10.1186\/s40168-021-01101-1","volume":"9","author":"DV Guzior","year":"2021","unstructured":"Guzior, D. V. & Quinn, R. A. Review: microbial transformations of human bile acids. Microbiome 9, 140 (2021).","journal-title":"Microbiome"},{"key":"531_CR30","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.3233\/JAD-215448","volume":"86","author":"K Kaleck\u00fd","year":"2022","unstructured":"Kaleck\u00fd, K., German, D. C., Montillo, A. A. & Bottiglieri, T. Targeted metabolomic analysis in Alzheimer\u2019s disease plasma and brain tissue in non-Hispanic whites. J. Alzheimers Dis. 86, 1875\u20131895 (2022).","journal-title":"J. Alzheimers Dis."},{"key":"531_CR31","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1007\/s11011-021-00808-2","volume":"36","author":"SA Moustafa","year":"2021","unstructured":"Moustafa, S. A. et al. Gut brain axis: An insight into microbiota role in Parkinson\u2019s disease. Metab. Brain Dis. 36, 1545\u20131557 (2021).","journal-title":"Metab. Brain Dis."},{"key":"531_CR32","doi-asserted-by":"publisher","first-page":"29","DOI":"10.3390\/metabo11010029","volume":"11","author":"P Li","year":"2021","unstructured":"Li, P. et al. Gut Microbiota dysbiosis is associated with elevated bile acids in Parkinson\u2019s disease. Metabolites 11, 29 (2021).","journal-title":"Metabolites"},{"key":"531_CR33","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s13024-021-00425-8","volume":"16","author":"Y Shao","year":"2021","unstructured":"Shao, Y. et al. Comprehensive metabolic profiling of Parkinson\u2019s disease by liquid chromatography-mass spectrometry. Mol. Neurodegener. 16, 4 (2021).","journal-title":"Mol. Neurodegener."},{"key":"531_CR34","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.3233\/JPD-223179","volume":"12","author":"S-J Chen","year":"2022","unstructured":"Chen, S.-J. et al. Alteration of gut microbial metabolites in the systemic circulation of patients with Parkinson\u2019s disease. J. Parkinsons. Dis. 12, 1219\u20131230 (2022).","journal-title":"J. Parkinsons. Dis."},{"key":"531_CR35","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1002\/ana.26454","volume":"92","author":"C Bolliri","year":"2022","unstructured":"Bolliri, C. et al. Gut Microbiota in monozygotic twins discordant for Parkinson\u2019s disease. Ann. Neurol. 92, 631\u2013636 (2022).","journal-title":"Ann. Neurol."},{"key":"531_CR36","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/S0076-6879(05)00022-4","volume":"400","author":"EM Shonsey","year":"2005","unstructured":"Shonsey, E. M. et al. Bile acid coenzyme A: Amino acid N-acyltransferase in the amino acid conjugation of bile acids. Methods Enzymol. 400, 374\u2013394 (2005).","journal-title":"Methods Enzymol."},{"key":"531_CR37","doi-asserted-by":"publisher","first-page":"585584","DOI":"10.3389\/fnins.2020.585584","volume":"14","author":"J Wang","year":"2020","unstructured":"Wang, J., Wang, F., Mai, D. & Qu, S. Molecular mechanisms of glutamate toxicity in Parkinson\u2019s disease. Front. Neurosci. 14, 585584 (2020).","journal-title":"Front. Neurosci."},{"key":"531_CR38","doi-asserted-by":"publisher","first-page":"867S","DOI":"10.3945\/ajcn.2009.27462BB","volume":"90","author":"RA Hawkins","year":"2009","unstructured":"Hawkins, R. A. The blood-brain barrier and glutamate. Am. J. Clin. Nutr. 90, 867S\u2013874S (2009).","journal-title":"Am. J. Clin. Nutr."},{"key":"531_CR39","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/0306-4522(93)90080-Y","volume":"57","author":"S Kato","year":"1993","unstructured":"Kato, S., Ishita, S., Sugawara, K. & Mawatari, K. Cystine\/glutamate antiporter expression in retinal M\u00fcller glial cells: implications for DL-alpha-aminoadipate toxicity. Neuroscience 57, 473\u2013482 (1993).","journal-title":"Neuroscience"},{"key":"531_CR40","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1111\/j.1460-9568.2008.06435.x","volume":"28","author":"RG Hu","year":"2008","unstructured":"Hu, R. G., Lim, J., Donaldson, P. J. & Kalloniatis, M. Characterization of the cystine\/glutamate transporter in the outer plexiform layer of the vertebrate retina. Eur. J. Neurosci. 28, 1491\u20131502 (2008).","journal-title":"Eur. J. Neurosci."},{"key":"531_CR41","doi-asserted-by":"publisher","first-page":"e1003","DOI":"10.1212\/WNL.0000000000006157","volume":"91","author":"J Ahn","year":"2018","unstructured":"Ahn, J. et al. Retinal thinning associates with nigral dopaminergic loss in de novo Parkinson disease. Neurology 91, e1003\u2013e1012 (2018).","journal-title":"Neurology"},{"key":"531_CR42","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-15065-7","volume":"11","author":"CL Vallerga","year":"2020","unstructured":"Vallerga, C. L. et al. Analysis of DNA methylation associates the cystine-glutamate antiporter SLC7A11 with risk of Parkinson\u2019s disease. Nat. Commun. 11, 1238 (2020).","journal-title":"Nat. Commun."},{"key":"531_CR43","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.freeradbiomed.2017.11.018","volume":"115","author":"NS Nemeria","year":"2018","unstructured":"Nemeria, N. S. et al. The mitochondrial 2-oxoadipate and 2-oxoglutarate dehydrogenase complexes share their E2 and E3 components for their function and both generate reactive oxygen species. Free Radic. Biol. Med. 115, 136\u2013145 (2018).","journal-title":"Free Radic. Biol. Med."},{"key":"531_CR44","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1007\/s10072-020-04626-9","volume":"42","author":"S Chaudhary","year":"2021","unstructured":"Chaudhary, S. et al. Frontal lobe metabolic alterations characterizing Parkinson\u2019s disease cognitive impairment. Neurol. Sci. 42, 1053\u20131064 (2021).","journal-title":"Neurol. Sci."},{"key":"531_CR45","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1006\/exnr.2002.7952","volume":"177","author":"C Gomes-Trolin","year":"2002","unstructured":"Gomes-Trolin, C., Nygren, I., Aquilonius, S.-M. & Askmark, H. Increased red blood cell polyamines in ALS and Parkinson\u2019s disease. Exp. Neurol. 177, 515\u2013520 (2002).","journal-title":"Exp. Neurol."},{"key":"531_CR46","doi-asserted-by":"publisher","first-page":"935","DOI":"10.3390\/ph14090935","volume":"14","author":"S Plewa","year":"2021","unstructured":"Plewa, S. et al. The metabolomic approach reveals the alteration in human serum and cerebrospinal fluid composition in Parkinson\u2019s disease patients. Pharm. (Basel) 14, 935 (2021).","journal-title":"Pharm. (Basel)"},{"key":"531_CR47","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1016\/j.cca.2010.05.034","volume":"411","author":"M-J Paik","year":"2010","unstructured":"Paik, M.-J. et al. Polyamine patterns in the cerebrospinal fluid of patients with Parkinson\u2019s disease and multiple system atrophy. Clin. Chim. Acta 411, 1532\u20131535 (2010).","journal-title":"Clin. Chim. Acta"},{"key":"531_CR48","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1038\/s41531-021-00239-x","volume":"7","author":"S Klatt","year":"2021","unstructured":"Klatt, S. et al. A six-metabolite panel as potential blood-based biomarkers for Parkinson\u2019s disease. NPJ Parkinsons Dis. 7, 94 (2021).","journal-title":"NPJ Parkinsons Dis."},{"key":"531_CR49","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1002\/mds.27173","volume":"32","author":"W Han","year":"2017","unstructured":"Han, W., Sapkota, S., Camicioli, R., Dixon, R. A. & Li, L. Profiling novel metabolic biomarkers for Parkinson\u2019s disease using in-depth metabolomic analysis. Mov. Disord. 32, 1720\u20131728 (2017).","journal-title":"Mov. Disord."},{"key":"531_CR50","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1017\/S0007114510001005","volume":"104","author":"K Murakami","year":"2010","unstructured":"Murakami, K. et al. Dietary intake of folate, vitamin B6, vitamin B12 and riboflavin and risk of Parkinson\u2019s disease: a case-control study in Japan. Br. J. Nutr. 104, 757\u2013764 (2010).","journal-title":"Br. J. Nutr."},{"key":"531_CR51","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.3389\/fimmu.2018.01070","volume":"9","author":"G Zhao","year":"2018","unstructured":"Zhao, G. et al. Betaine in inflammation: Mechanistic aspects and applications. Front. Immunol. 9, 1070 (2018).","journal-title":"Front. Immunol."},{"key":"531_CR52","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1111\/jnc.12094","volume":"124","author":"G-S Chai","year":"2013","unstructured":"Chai, G.-S. et al. Betaine attenuates Alzheimer-like pathological changes and memory deficits induced by homocysteine. J. Neurochem. 124, 388\u2013396 (2013).","journal-title":"J. Neurochem."},{"key":"531_CR53","doi-asserted-by":"publisher","first-page":"e22090","DOI":"10.1002\/jcla.22090","volume":"31","author":"J Sun","year":"2017","unstructured":"Sun, J., Wen, S., Zhou, J. & Ding, S. Association between malnutrition and hyperhomocysteine in Alzheimer\u2019s disease patients and diet intervention of betaine. J. Clin. Lab. Anal. 31, e22090 (2017).","journal-title":"J. Clin. Lab. Anal."},{"key":"531_CR54","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1007\/s00702-018-1903-3","volume":"126","author":"T Nagatsu","year":"2019","unstructured":"Nagatsu, T., Nakashima, A., Ichinose, H. & Kobayashi, K. Human tyrosine hydroxylase in Parkinson\u2019s disease and in related disorders. J. Neural Transm. (Vienna) 126, 397\u2013409 (2019).","journal-title":"J. Neural Transm. (Vienna)"},{"key":"531_CR55","doi-asserted-by":"publisher","DOI":"10.1038\/srep36749","volume":"6","author":"Y Irino","year":"2016","unstructured":"Irino, Y. et al. 2-Aminobutyric acid modulates glutathione homeostasis in the myocardium. Sci. Rep. 6, 36749 (2016).","journal-title":"Sci. Rep."},{"key":"531_CR56","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/S0022-510X(97)00069-5","volume":"150","author":"JA Molina","year":"1997","unstructured":"Molina, J. A. et al. Decreased cerebrospinal fluid levels of neutral and basic amino acids in patients with Parkinson\u2019s disease. J. Neurol. Sci. 150, 123\u2013127 (1997).","journal-title":"J. Neurol. Sci."},{"key":"531_CR57","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/S0197-0186(99)00150-3","volume":"36","author":"SR Robinson","year":"2000","unstructured":"Robinson, S. R. Neuronal expression of glutamine synthetase in Alzheimer\u2019s disease indicates a profound impairment of metabolic interactions with astrocytes. Neurochem. Int. 36, 471\u2013482 (2000).","journal-title":"Neurochem. Int."},{"key":"531_CR58","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/j.neuint.2009.12.021","volume":"56","author":"J Zou","year":"2010","unstructured":"Zou, J. et al. Glutamine synthetase down-regulation reduces astrocyte protection against glutamate excitotoxicity to neurons. Neurochem. Int. 56, 577\u2013584 (2010).","journal-title":"Neurochem. Int."},{"key":"531_CR59","doi-asserted-by":"publisher","first-page":"3119","DOI":"10.1007\/s12035-021-02327-8","volume":"58","author":"L Streubel-Gallasch","year":"2021","unstructured":"Streubel-Gallasch, L. et al. Parkinson\u2019s disease-associated LRRK2 interferes with astrocyte-mediated alpha-synuclein clearance. Mol. Neurobiol. 58, 3119\u20133140 (2021).","journal-title":"Mol. Neurobiol."},{"key":"531_CR60","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1007\/s12035-021-02583-8","volume":"59","author":"EI Fedotova","year":"2022","unstructured":"Fedotova, E. I., Dolgacheva, L. P., Abramov, A. Y. & Berezhnov, A. V. Lactate and pyruvate activate autophagy and mitophagy that protect cells in toxic model of Parkinson\u2019s disease. Mol. Neurobiol. 59, 177\u2013190 (2022).","journal-title":"Mol. Neurobiol."},{"key":"531_CR61","doi-asserted-by":"publisher","first-page":"14028","DOI":"10.1074\/jbc.M110.182329","volume":"286","author":"MOW Grimm","year":"2011","unstructured":"Grimm, M. O. W. et al. Docosahexaenoic acid reduces amyloid beta production via multiple pleiotropic mechanisms. J. Biol. Chem. 286, 14028\u201314039 (2011).","journal-title":"J. Biol. Chem."},{"key":"531_CR62","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.brainres.2012.08.039","volume":"1478","author":"LA Knebel","year":"2012","unstructured":"Knebel, L. A. et al. 2-Methylbutyrylglycine induces lipid oxidative damage and decreases the antioxidant defenses in rat brain. Brain Res 1478, 74\u201382 (2012).","journal-title":"Brain Res"},{"key":"531_CR63","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1002\/mds.26119","volume":"30","author":"CW Olanow","year":"2015","unstructured":"Olanow, C. W. Levodopa: effect on cell death and the natural history of Parkinson\u2019s disease: Levodopa and the Natural History of PD. Mov. Disord. 30, 37\u201344 (2015).","journal-title":"Mov. Disord."},{"key":"531_CR64","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1056\/NEJM197210122871501","volume":"287","author":"CR Sirtori","year":"1972","unstructured":"Sirtori, C. R., Bolme, P. & Azarnoff, D. L. Metabolic responses to acute and chronic L-dopa administration in patients with parkinsonism. N. Engl. J. Med. 287, 729\u2013733 (1972).","journal-title":"N. Engl. J. Med."},{"key":"531_CR65","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1007\/s00228-008-0532-4","volume":"64","author":"F Adams","year":"2008","unstructured":"Adams, F. et al. Influences of levodopa on adipose tissue and skeletal muscle metabolism in patients with idiopathic Parkinson\u2019s disease. Eur. J. Clin. Pharmacol. 64, 863\u2013870 (2008).","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"531_CR66","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1097\/00001756-199906230-00016","volume":"10","author":"M Tanaka","year":"1999","unstructured":"Tanaka, M., Yoshida, T., Okamoto, K. & Hirai, S. Dopamine and DOPA cause release of iron from ferritin and lipid peroxidation of liposomes. Neuroreport 10, 1883\u20131887 (1999).","journal-title":"Neuroreport"},{"key":"531_CR67","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.1016\/j.freeradbiomed.2004.08.009","volume":"37","author":"KJ Rodgers","year":"2004","unstructured":"Rodgers, K. J., Hume, P. M., Dunlop, R. A. & Dean, R. T. Biosynthesis and turnover of DOPA-containing proteins by human cells. Free Radic. Biol. Med. 37, 1756\u20131764 (2004).","journal-title":"Free Radic. Biol. Med."},{"key":"531_CR68","doi-asserted-by":"publisher","first-page":"105624","DOI":"10.1016\/j.biocel.2019.105624","volume":"117","author":"S Giannopoulos","year":"2019","unstructured":"Giannopoulos, S., Samardzic, K., Raymond, B. B. A., Djordjevic, S. P. & Rodgers, K. J. L-DOPA causes mitochondrial dysfunction in vitro: A novel mechanism of L-DOPA toxicity uncovered. Int. J. Biochem. Cell Biol. 117, 105624 (2019).","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"531_CR69","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1097\/WNF.0000000000000408","volume":"43","author":"A Rojo-Sebasti\u00e1n","year":"2020","unstructured":"Rojo-Sebasti\u00e1n, A., Gonz\u00e1lez-Robles, C. & Garc\u00eda de Y\u00e9benes, J. Vitamin B6 deficiency in patients with Parkinson disease treated with levodopa\/carbidopa. Clin. Neuropharmacol. 43, 151\u2013157 (2020).","journal-title":"Clin. Neuropharmacol."},{"key":"531_CR70","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1002\/iub.2507","volume":"74","author":"G Olaso-Gonzalez","year":"2022","unstructured":"Olaso-Gonzalez, G. et al. Impact of supplementation with vitamins B6, B12, and\/or folic acid on the reduction of homocysteine levels in patients with mild cognitive impairment: A systematic review. IUBMB Life 74, 74\u201384 (2022).","journal-title":"IUBMB Life"},{"key":"531_CR71","doi-asserted-by":"publisher","first-page":"2468","DOI":"10.1096\/fj.12-219055","volume":"27","author":"S-C Lai","year":"2013","unstructured":"Lai, S.-C. et al. The transcobalamin receptor knockout mouse: a model for vitamin B12 deficiency in the central nervous system. FASEB J. 27, 2468\u20132475 (2013).","journal-title":"FASEB J."},{"key":"531_CR72","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1615\/CritRevImmunol.v37.i2-6.20","volume":"37","author":"M Murakami","year":"2017","unstructured":"Murakami, M., Nakatani, Y., Atsumi, G.-I., Inoue, K. & Kudo, I. Regulatory functions of phospholipase A2. Crit. Rev. Immunol. 37, 127\u2013195 (2017).","journal-title":"Crit. Rev. Immunol."},{"key":"531_CR73","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/S0005-2728(05)80332-9","volume":"1098","author":"M Kalous","year":"1992","unstructured":"Kalous, M., Rauchov\u00e1, H. & Drahota, Z. The effect of lysophosphatidylcholine on the activity of various mitochondrial enzymes. Biochim. Biophys. Acta. 1098, 167\u2013171 (1992).","journal-title":"Biochim. Biophys. Acta."},{"key":"531_CR74","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.steroids.2018.09.003","volume":"139","author":"MH Cha","year":"2018","unstructured":"Cha, M. H., Lee, S. M. & Jung, J. Lysophosphatidylcholine induces expression of genes involved in cholesterol biosynthesis in THP-1 derived macrophages. Steroids 139, 28\u201334 (2018).","journal-title":"Steroids"},{"key":"531_CR75","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-06767-y","volume":"7","author":"S Saiki","year":"2017","unstructured":"Saiki, S. et al. Decreased long-chain acylcarnitines from insufficient \u03b2-oxidation as potential early diagnostic markers for Parkinson\u2019s disease. Sci. Rep. 7, 7328 (2017).","journal-title":"Sci. Rep."},{"key":"531_CR76","doi-asserted-by":"publisher","first-page":"105065","DOI":"10.1016\/j.neuint.2021.105065","volume":"147","author":"Y Gou","year":"2021","unstructured":"Gou, Y. et al. Homocysteine restrains hippocampal neurogenesis in focal ischemic rat brain by inhibiting DNA methylation. Neurochem. Int. 147, 105065 (2021).","journal-title":"Neurochem. Int."},{"key":"531_CR77","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1097\/MCO.0b013e32834d199f","volume":"15","author":"AK Elshorbagy","year":"2012","unstructured":"Elshorbagy, A. K., Kozich, V., Smith, A. D. & Refsum, H. Cysteine and obesity: consistency of the evidence across epidemiologic, animal and cellular studies. Curr. Opin. Clin. Nutr. Metab. Care 15, 49\u201357 (2012).","journal-title":"Curr. Opin. Clin. Nutr. Metab. Care"},{"key":"531_CR78","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1089\/dna.2007.0658","volume":"27","author":"J Yideng","year":"2008","unstructured":"Yideng, J. et al. Homocysteine-mediated PPARalpha,gamma DNA methylation and its potential pathogenic mechanism in monocytes. DNA Cell Biol. 27, 143\u2013150 (2008).","journal-title":"DNA Cell Biol."},{"key":"531_CR79","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1096\/fj.201600915R","volume":"31","author":"K Khayati","year":"2017","unstructured":"Khayati, K. et al. The amino acid metabolite homocysteine activates mTORC1 to inhibit autophagy and form abnormal proteins in human neurons and mice. FASEB J. 31, 598\u2013609 (2017).","journal-title":"FASEB J."},{"key":"531_CR80","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1080\/15548627.2019.1609847","volume":"15","author":"HWS Tan","year":"2019","unstructured":"Tan, H. W. S. et al. Lysosomal inhibition attenuates peroxisomal gene transcription via suppression of PPARA and PPARGC1A levels. Autophagy 15, 1455\u20131459 (2019).","journal-title":"Autophagy"},{"key":"531_CR81","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.molcel.2019.08.005","volume":"76","author":"H Zhang","year":"2019","unstructured":"Zhang, H. et al. Polyamines control eIF5A hypusination, TFEB translation, and autophagy to reverse B cell senescence. Mol. Cell 76, 110\u2013125.e9 (2019).","journal-title":"Mol. Cell"},{"key":"531_CR82","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1016\/j.cmet.2019.05.003","volume":"30","author":"DJ Puleston","year":"2019","unstructured":"Puleston, D. J. et al. Polyamines and eIF5A hypusination modulate mitochondrial respiration and macrophage activation. Cell Metab. 30, 352\u2013363.e8 (2019).","journal-title":"Cell Metab."},{"key":"531_CR83","doi-asserted-by":"publisher","first-page":"397","DOI":"10.3390\/nu13020397","volume":"13","author":"N Masuoka","year":"2021","unstructured":"Masuoka, N., Lei, C., Li, H. & Hisatsune, T. Influence of imidazole-dipeptides on cognitive status and preservation in elders: A narrative review. Nutrients 13, 397 (2021).","journal-title":"Nutrients"},{"key":"531_CR84","doi-asserted-by":"publisher","DOI":"10.1186\/s40064-015-1074-8","volume":"4","author":"S Suidasari","year":"2015","unstructured":"Suidasari, S., Hasegawa, T., Yanaka, N. & Kato, N. Dietary supplemental vitamin B6 increases carnosine and anserine concentrations in the heart of rats. Springerplus 4, 280 (2015).","journal-title":"Springerplus"},{"key":"531_CR85","doi-asserted-by":"publisher","first-page":"e1701062","DOI":"10.1002\/mnfr.201701062","volume":"62","author":"B Kochlik","year":"2018","unstructured":"Kochlik, B., Gerbracht, C., Grune, T. & Weber, D. The influence of dietary habits and meat consumption on plasma 3-methylhistidine-A potential marker for muscle protein turnover. Mol. Nutr. Food Res. 62, e1701062 (2018).","journal-title":"Mol. Nutr. Food Res."},{"key":"531_CR86","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.cca.2019.10.038","volume":"501","author":"B Sankowski","year":"2020","unstructured":"Sankowski, B. et al. Higher cerebrospinal fluid to plasma ratio of p-cresol sulfate and indoxyl sulfate in patients with Parkinson\u2019s disease. Clin. Chim. Acta. 501, 165\u2013173 (2020).","journal-title":"Clin. Chim. Acta."},{"key":"531_CR87","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1111\/neup.12189","volume":"35","author":"TG Beach","year":"2015","unstructured":"Beach, T. G. et al. Arizona Study of Aging and Neurodegenerative Disorders and brain and Body Donation Program: Arizona brain and body donation program. Neuropathology 35, 354\u2013389 (2015).","journal-title":"Neuropathology"},{"key":"531_CR88","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1192\/bjp.140.6.566","volume":"140","author":"CP Hughes","year":"1982","unstructured":"Hughes, C. P., Berg, L., Danziger, W. L., Coben, L. A. & Martin, R. L. A new clinical scale for the staging of dementia. Br. J. Psychiatry 140, 566\u2013572 (1982).","journal-title":"Br. J. Psychiatry"},{"key":"531_CR89","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/S0197-4580(97)00057-2","volume":"18","author":"Consensus recommendations for the postmortem diagnosis of Alzheimer\u2019s disease.","year":"1997","unstructured":"Consensus recommendations for the postmortem diagnosis of Alzheimer\u2019s disease. The National Institute on Aging, and Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer\u2019s Disease. Neurobiol. Aging 18, S1\u2013S2 (1997).","journal-title":"Neurobiol. Aging"},{"key":"531_CR90","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1212\/WNL.41.4.479","volume":"41","author":"SS Mirra","year":"1991","unstructured":"Mirra, S. S. et al. The Consortium to Establish a Registry for Alzheimer\u2019s Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer\u2019s disease. Neurology 41, 479\u2013486 (1991).","journal-title":"Neurology"},{"key":"531_CR91","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1159\/000321984","volume":"31","author":"S Crean","year":"2011","unstructured":"Crean, S. et al. Apolipoprotein E \u03b54 prevalence in Alzheimer\u2019s disease patients varies across global populations: A systematic literature review and meta-analysis. Dement. Geriatr. Cogn. Disord. 31, 20\u201330 (2011).","journal-title":"Dement. Geriatr. Cogn. Disord."},{"key":"531_CR92","first-page":"3","volume":"10","author":"A Limonciel","year":"2020","unstructured":"Limonciel, A. et al. MetaboINDICATOR\u2122: Translate Metabolomics & Lipidomics into Knowledge. MetaboNews 10, 3\u20135 (2020). http:\/\/www.metabonews.ca\/Feb2020\/MetaboNews_Feb2020.pdf.","journal-title":"MetaboNews"},{"key":"531_CR93","doi-asserted-by":"publisher","first-page":"23","DOI":"10.11120\/msor.2001.01010023","volume":"1","author":"BD Ripley","year":"2001","unstructured":"Ripley, B. D. The R project in statistical computing. MSOR connect 1, 23\u201325 (2001).","journal-title":"MSOR connect"},{"key":"531_CR94","unstructured":"RStudio Team. RStudio: Integrated Development for R. (RStudio, Inc.), (2019). http:\/\/www.rstudio.com"},{"key":"531_CR95","doi-asserted-by":"crossref","unstructured":"Fox, J. & Weisberg, S. An R companion to applied regression. (SAGE Publications), (2018).","DOI":"10.32614\/CRAN.package.carData"},{"key":"531_CR96","unstructured":"Tukey, J. W. Exploratory Data Analysis. (Addison-Wesley), (1977)."},{"key":"531_CR97","unstructured":"Pinheiro, J., Bates, D., DebRoy, S., Sarkar, D. & R Core Team. nlme: Linear and Nonlinear Mixed Effects Models [R Package Version 3.1-152]. The Comprehensive R Archive Network https:\/\/CRAN.R-project.org\/package=nlme (2021)."},{"key":"531_CR98","unstructured":"Storey, J. D., Bass, A. J., Dabney, A. & Robinson, D. Qvalue: Q-value estimation for false discovery rate control [R package qvalue version 2.18.0]. GitHub http:\/\/github.com\/jdstorey\/qvalue (2019)."},{"key":"531_CR99","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-15231-w","volume":"7","author":"DK Barupal","year":"2017","unstructured":"Barupal, D. K. & Fiehn, O. Chemical Similarity Enrichment Analysis (ChemRICH) as alternative to biochemical pathway mapping for metabolomic datasets. Sci. Rep. 7, 14567 (2017).","journal-title":"Sci. Rep."},{"key":"531_CR100","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2105-12-77","volume":"12","author":"X Robin","year":"2011","unstructured":"Robin, X. et al. pROC: an open-source package for R and S+ to analyze and compare ROC curves. BMC Bioinforma. 12, 77 (2011).","journal-title":"BMC Bioinforma."}],"container-title":["npj Parkinson's Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41531-023-00531-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41531-023-00531-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41531-023-00531-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,21]],"date-time":"2024-10-21T19:28:53Z","timestamp":1729538933000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41531-023-00531-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,3]]},"references-count":100,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["531"],"URL":"https:\/\/doi.org\/10.1038\/s41531-023-00531-y","relation":{},"ISSN":["2373-8057"],"issn-type":[{"value":"2373-8057","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,3]]},"assertion":[{"value":"22 October 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"84"}}